Estimated incidence of symptomatic Lyme borreliosis cases in five southern coastal counties in Norway, 2022
- Published on 22/07/2025
- Reading time: 7 min.
Emily Colby 1, Tor Molden 2, Julia Olsen 1, Patrick Kelly 1, Andreas Pilz 3, Kate Halsby 4, Gordon Brestrich 5, Frederick J. Angulo 1, Jennifer C. Moïsi 6, James H. Stark 7
1
Vaccines, Antivirals, and Evidence Generation
Pfizer Biopharma Group
Collegeville
Pennsylvania
USA
2
Pfizer AS
Lysaker
Norway
3
Vaccines, Pfizer Corporation Austria
Vienna
Austria
4
Pfizer Vaccines
Surrey
UK
5
Pfizer Vaccines
Pfizer Pharma GmbH
Berlin
Germany
6
Pfizer Vaccines
Paris
France
7
Vaccines, Antivirals, and Evidence Generation
Pfizer Biopharma Group
Cambridge
Massachusetts
USA
Hologic, Inc
Marlborough
Massachusetts
USA
Abstract
Lyme borreliosis (LB), the most common tick‐borne disease in Europe, is endemic to southern coastal Norway. LB commonly presents as erythema migrans, which can disseminate, resulting in more severe disease such as Lyme neuroborreliosis or arthritis. In Norway, public health LB surveillance is conducted via mandatory reporting of laboratory‐confirmed disseminated cases. From 2012 to 2022, Norway's surveillance‐reported incidence of laboratory‐confirmed...
To continue reading this article in Full-Text...
Search | Advanced search
Articles by topics
